Journal of Clinical Trials
Open Access
ISSN: 2167-0870
+44 1478 350008
ISSN: 2167-0870
+44 1478 350008
Department of Ophthalmology, MelmaruvathurAdhiparasakthi Institute of Medical Sciences and Research, Kancheepuram, Tamil Nadu, India
Review Article
Convalescent Plasma as a Plausible Therapeutic Option for nCOVID-19: A Review
Author(s): Talagavadi Channaiah Anudeep, Madhan Jeyaraman*, Dharma U Shetty, Hemmanth Raj M, Ajay SS, Rajeswari Somasundaram, Vinodh Kumar V, Rashmi Jain and ShirodkarJaswandi Dilip
The world is battling a pandemic caused by the newly emerged strain of coronavirus; upon identification SARSCoV-2 and in interim named nCOVID-19 by the World Health Organization (WHO). The contagion has sparked a war against humanity with the current global toll of 1,12,241 human lives. Till date no definitive treatment against SARS-CoV-2 has been established. Similar picture of lack of licensed definitive therapy can be traced back to Ebola outbreak and the WHO directed for considering convalescent plasma (CP) therapy for its control. The history of CP as therapeutics dates back to 20th century which renders a scope for consideration in the management of nCOVID-19. Experience from prior outbreak of SARS-CoV-1 has shown that convalescent sera contain neutralizing antibodies to the relevant virus. The core principle of this passive antibody therapy is based on retrieving virus neutrali.. View More»
DOI:
10.35248/2167-0870.20.10.409